Navigation Links
Drug Effective Against Heart-Lung Disorder
Date:6/19/2008

Bosentan slowed decline linked to pulmonary arterial hypertension, study found

THURSDAY, June 19 (HealthDay News) -- The drug bosentan reduced clinical decline in patients with early-stage pulmonary arterial hypertension (PAH), Italian researchers report.

PAH is a progressive disease in which increased pulmonary resistance in the lungs causes structural damage to the heart, eventually leading to heart failure and death.

Previous studies have shown that bosentan improves exercise capacity and pulmonary vascular resistance (PVR) and slows clinical decline in patients with later stages of PAH.

This new study included 185 people, ages 12 and over, with early-stage PAH who were divided into two groups. One group received bosentan, and the other group received a placebo. The patients' PVR and distance they could walk in six minutes were measured at the start of the study and again six months later.

After six months, the mean PVR improved at a significant rate for those on bosentan versus those on placebo, wrote Professor Nazzareno Galie, of the Institute of Cardiology at the University of Bologna, and colleagues.

The mean six-minute walk distance also increased 11.2 meters in the bosentan group from 438 meters at baseline, compared to a decrease from 431 meters to 423 meters in the placebo group. However, these changes in distance weren't clinically significant.

Three percent of patients in the bosentan group and 14 percent of those in the placebo group experienced clinical worsening events, such as symptomatic progression of PAH, hospitalization and death. This difference was statistically significant.

Thirteen percent of patients in the bosentan group and 9 percent of those in the placebo group reported serious adverse events. Fainting was the most common adverse event in the bosentan group, and right ventricular failure was the most common in the placebo group.

The findings are in the June 21 issue of The Lancet.

"This study broadens the potential for bosentan as a treatment in pulmonary arterial hypertension, and the evidence presented by (the researchers) should soon be translated into clinical practice," Dr. Neeraj Dhaun and Professor David Webb, Queen's Medical Research Institute, University of Edinburgh, U.K., wrote in an accompanying comment.

More information

The U.S. National Heart, Lung, and Blood Institute has more about PAH.



-- Robert Preidt



SOURCE: The Lancet, news release, June 20, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Build and Maintain an Effective Competitive Intelligence Group
2. Healthways Proves Effectiveness of Senior Fitness Program with QualityMetric Health Survey
3. HIV Tests Cost-Effective for Some Seniors
4. Effective health messages may yield vaccine compliance among ER workers
5. Effective treatment for sickle cell underused by doctors
6. Effective Communication of Clinical Studies for Maximum Impact
7. Winning Method - Effective Identification and Development of Clinical Investigators
8. Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapies
9. Hand bone mineral density is an effective predictor of mortality in rheumatoid arthritis
10. Whole Milk Cheaper, Effective Contrast Agent for GI Scans
11. Tracking Cancer Drugs Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Effective Against Heart-Lung Disorder
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri Agency, an insurance ... Collins area, has unveiled a collaboration with nonprofit Big Bones Canine Rescue as ... worthy cause may now be made at http://bigbonescaninerescue.com/ . , Big Bones ...
(Date:3/23/2017)... ... March 23, 2017 , ... Altec Products, Inc. , ... as their 2016 Microsoft Dynamics Partner of the Year at DocLink Evolution ... award recognizes The Resource Group for their outstanding relationship with Altec and their ...
(Date:3/23/2017)... ... March 23, 2017 , ... Sharon Kleyne, host of ... Change and Your Health on VoiceAmerica, recently talked on her program about how she ... the occasion to remind listeners of an important distinction. World Water Day, Kleyne pointed ...
(Date:3/23/2017)... Kennett Square, PA (PRWEB) , ... March 23, 2017 , ... ... sunny days. That means many students are thinking about summer internships , which ... (or lack thereof). , The pros at Garden Media Group, a boutique public relations ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The American ... 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management ... who have contributed not only to the association, but also to the Health Care ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... SILVER SPRING, Md. , March 23, 2017 /PRNewswire-USNewswire/ ... approval to Bavencio (avelumab) for the treatment of adults ... Merkel cell carcinoma (MCC), including those who have not ... for metastatic MCC, a rare, aggressive form of skin ... the most common cancers, patients with a rare form ...
(Date:3/23/2017)... VANCOUVER, British Columbia , March 23, 2017 ... (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company ... today announced that data from its successful Phase 2a ... focal treatment for localized prostate cancer, will be presented ... 32 nd Annual European Association of Urology in ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... offering. ... global oxygen therapy devices market to grow at a CAGR of ... Oxygen Therapy Devices Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
Breaking Medicine Technology: